Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

terminated250%
active_not_recruiting125%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
terminatedphase_2

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

NCT04873869
active_not_recruitingphase_2

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

NCT05226780
completedphase_2

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

NCT05159908
terminatedphase_2

Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

NCT05493293

Clinical Trials (4)

Showing 4 of 4 trials
NCT04873869Phase 2

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Terminated
NCT05226780Phase 2

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

Active Not Recruiting
NCT05159908Phase 2

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Completed
NCT05493293Phase 2

Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4